DE69232585D1 - Oligosidderivat aus einem polyosidantigen von einem pathogenen erreger - Google Patents

Oligosidderivat aus einem polyosidantigen von einem pathogenen erreger

Info

Publication number
DE69232585D1
DE69232585D1 DE69232585T DE69232585T DE69232585D1 DE 69232585 D1 DE69232585 D1 DE 69232585D1 DE 69232585 T DE69232585 T DE 69232585T DE 69232585 T DE69232585 T DE 69232585T DE 69232585 D1 DE69232585 D1 DE 69232585D1
Authority
DE
Germany
Prior art keywords
oligoside
pathogenic
polyosidantant
exciter
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232585T
Other languages
English (en)
Other versions
DE69232585T2 (de
Inventor
Monique Moreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur SA filed Critical Aventis Pasteur SA
Application granted granted Critical
Publication of DE69232585D1 publication Critical patent/DE69232585D1/de
Publication of DE69232585T2 publication Critical patent/DE69232585T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE69232585T 1991-10-10 1992-10-09 Oligosidderivat aus einem polyosidantigen von einem pathogenen erreger Expired - Lifetime DE69232585T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9112478A FR2682388B1 (fr) 1991-10-10 1991-10-10 Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
PCT/FR1992/000955 WO1993007178A1 (fr) 1991-10-10 1992-10-09 Oligoside derive d'un polyoside antigenique issu d'un agent pathogene

Publications (2)

Publication Number Publication Date
DE69232585D1 true DE69232585D1 (de) 2002-06-06
DE69232585T2 DE69232585T2 (de) 2002-12-05

Family

ID=9417772

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232585T Expired - Lifetime DE69232585T2 (de) 1991-10-10 1992-10-09 Oligosidderivat aus einem polyosidantigen von einem pathogenen erreger

Country Status (15)

Country Link
US (2) US6045805A (de)
EP (1) EP0562107B1 (de)
JP (1) JP3676803B2 (de)
KR (1) KR100249709B1 (de)
AT (1) ATE217015T1 (de)
AU (1) AU661071B2 (de)
CA (1) CA2098105C (de)
DE (1) DE69232585T2 (de)
DK (1) DK0562107T3 (de)
ES (1) ES2174839T3 (de)
FI (1) FI110164B (de)
FR (1) FR2682388B1 (de)
HU (1) HU219672B (de)
NO (1) NO306905B1 (de)
WO (1) WO1993007178A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT658118E (pt) * 1992-08-31 2002-05-31 Baxter Healthcare Sa Vacinas contra neisseria meningitidis do grupo c
NZ248766A (en) * 1992-09-24 1996-11-26 Ca Nat Research Council Capsular polysaccharide-protein conjugate vaccine against group b streptococcus type ii or v
US5514665A (en) * 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5738855A (en) * 1994-10-17 1998-04-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US6284884B1 (en) * 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
FR2748476B1 (fr) * 1996-05-07 1998-08-14 Pf Medicament Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
EP1035137A1 (de) * 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Verfahren zur reduktiven aminierung von polysacchariden
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
RO122761B1 (ro) 2001-01-23 2010-01-29 Aventis Pasteur Vaccin multivalent antimeningococic conţinând polizaharid-proteină
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP2402753A1 (de) * 2002-03-11 2012-01-04 Momenta Pharmaceuticals, Inc. Analyse von sulfatierten Polysacchariden
PT1490409E (pt) * 2002-03-26 2009-04-03 Novartis Vaccines & Diagnostic Sacáridos modificados possuindo uma estabilidade melhorada em água
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
EP1603950A2 (de) * 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutiertes choleraholotoxin als adjuvans und antigenträgerprotein
CA2530434A1 (en) 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
WO2005044861A1 (en) * 2003-10-31 2005-05-19 Wyeth Holdings Corporation Polysaccharides of helicobacter pylori
US20060039899A1 (en) * 2004-08-23 2006-02-23 Winn Robert T Animal nutritional product that increases weight gain and reduces diarrhea morbidity, mortality and severity by stimulation of natural immune response, nutritional support of immune function and supplemental nutricines and probiotics
FR2884830A1 (fr) * 2005-04-25 2006-10-27 Sanofi Pasteur Sa Procede de production de souches de staphylococcus aureus surproductrices
FR2899110A1 (fr) * 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
JP2013506651A (ja) 2009-09-30 2013-02-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ．ａｕｒｅｕｓ５型および８型莢膜多糖の結合体
PT2493498T (pt) * 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
EP2526122B1 (de) * 2010-01-19 2020-06-10 Momenta Pharmaceuticals, Inc. Beurteilung von heparinzubereitungen
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
SI3506935T1 (sl) 2016-09-02 2024-06-28 Sanofi Pasteur, Inc. Cepivo proti neisseriji meningitidis
US11197921B2 (en) 2017-01-31 2021-12-14 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
SE8200751L (sv) * 1982-02-09 1983-08-10 Olle Larm Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter
NL8202527A (nl) * 1982-06-22 1984-01-16 Univ Utrecht Vaccins tegen door bacterien met kapsel-polysacchariden verwekte ziekten en werkwijze voor het bereiden daarvan.
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
CA1291423C (en) * 1985-10-24 1991-10-29 Ping W. Tang Biochemical reagent
EP0302887B1 (de) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Bakterielle antigene, antikörper, impfstoffe und deren herstellung
US5302386A (en) * 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
AR243540A1 (es) * 1986-08-05 1993-08-31 Ajorca Sa Procedimiento quimico para la depolimerizacion controlada de polianiones naturales y productos asi obtenidos, excluidos sus usos farmaceuticos.
US5204098A (en) * 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5476929A (en) * 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5370872A (en) * 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines

Also Published As

Publication number Publication date
DK0562107T3 (da) 2002-08-19
DE69232585T2 (de) 2002-12-05
KR930703362A (ko) 1993-11-29
NO932102D0 (no) 1993-06-09
FI932626A0 (fi) 1993-06-09
FR2682388B1 (fr) 1995-06-09
US6045805A (en) 2000-04-04
US6007818A (en) 1999-12-28
CA2098105C (fr) 2003-04-29
FR2682388A1 (fr) 1993-04-16
FI110164B (fi) 2002-12-13
EP0562107A1 (de) 1993-09-29
HU219672B (hu) 2001-06-28
JP3676803B2 (ja) 2005-07-27
AU661071B2 (en) 1995-07-13
NO306905B1 (no) 2000-01-10
WO1993007178A1 (fr) 1993-04-15
HU9301682D0 (en) 1993-10-28
FI932626A (fi) 1993-06-09
ES2174839T3 (es) 2002-11-16
EP0562107B1 (de) 2002-05-02
NO932102L (no) 1993-08-05
ATE217015T1 (de) 2002-05-15
CA2098105A1 (fr) 1993-04-10
HUT70298A (en) 1995-09-28
AU2946992A (en) 1993-05-03
JPH06506233A (ja) 1994-07-14
KR100249709B1 (ko) 2000-03-15

Similar Documents

Publication Publication Date Title
DE69232585D1 (de) Oligosidderivat aus einem polyosidantigen von einem pathogenen erreger
FI923023A (fi) Implantationsmaterial aostadkommande naervaskularisation.
NO973167D0 (no) Bestemte 1,4,5-trisubstituerte imidazole-forbindelser anvendelige som cytokin
NO975387D0 (no) Fremgangsmåte for fremstilling av 3-haloalkyl-1H-pyrazoler
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
ES2139094T3 (es) Componentes cataliticos puenteados de amido-siladiilo, metodo de fabricacion y uso.
TR199701146T1 (xx) N�rotensin resept�rleri �zerinde etkili 1-Fenilpirazol-3-Karboksamidler.
PL289487A1 (en) Method of producing new aminophenol derivatives
NL191314C (nl) 3-Monogesubstitueerd-1-azetidine-carboxamidederivaat, alsmede een anticonvulsief preparaat.
EA199800230A1 (ru) Тетрагидрохинолины в качестве антагонистов nmda (n-метил-d-аспарагиновой кислоты)
DE69011471D1 (de) Lagerfähige, gelformende Einkomponentenfluorosiloxan-Zusammensetzungen mit verbesserter Hitzestabilität.
FI951378A0 (fi) N-asetyyli-neuramiinihapon johdannaisten synteesi
ES2185196T3 (es) Un procedimiento para la preparacion de tetraazamacrociclos.
FR2513122B1 (de)
DE69015127D1 (de) Lagerfähige, gelformende Einkomponenten-Fluorsiloxanzusammensetzungen.
KR840006230A (ko) 1-페닐-2-메틸-3-(1-피로리디닐)-1-프로판온 유도체의 제조방법
ES2157419T3 (es) Arilazadioxacicloalquenos substituidos, fungicidas.
MX173047B (es) Procedimiento para preparar un compuesto de trifluormetilvinilo
DE69724563D1 (de) Verfahren zur Herstellung von N-hydrocarbyl-substituierten Amiden
TR199700790T1 (xx) S�bstit�te edilmi� heterosikloalkenler.
SE9602416D0 (sv) New forms of an organic salt of N'N-diacetylcystine
FR2671974B1 (de)
ATE34386T1 (de) 1,2,3,4-tetrahydro-1-aminomethyl-4-phenylisochinoline und verfahren zu ihrer herstellung.
ATE261436T1 (de) Verfahren zu herstellung von substituierten pyranen
EA200200491A1 (ru) Замещенные 1,2,3,4,5,6-гексагидро-2,6-метано-3-бензазоцины и их применение в качестве лекарственных средств

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 562107

Country of ref document: EP